Clinical Trial Ceftriaxone in Subjects With ALS (OMOP)

syn72379208

The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS). Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years. The goals of this study are to evaluate the safety and effectiveness of ceftriaxone as a treatment for ALS, and to determine the safety and effectiveness of long-term use of the drug in people with ALS.
Created By Ram Ayyala ram.ayyala

url: https://fair.dap.c-path.org/#/data/datasets/omop_als1001
title: Clinical Trial Ceftriaxone in Subjects With ALS [OMOP]
sameAs: cpath:1960
source: Critical Path Institute
creator: Massachusetts General Hospital
species: Homo sapiens
subject: amyotrophic lateral sclerosis
keywords: ALS Amyotrophic Lateral Sclerosis disorder neurodegenerative placebo cephalosporin antibiotic motor neurons
publisher: Critical Path Institute
collection: ALS Knowledge Portal
contributor: Massachusetts General Hospital

Clinical Trial Ceftriaxone in Subjects With ALS (OMOP) page is loading…